A Study of Qishenyiqi Dripping Pills in Healthy Participants
NCT ID: NCT04471298
Last Updated: 2021-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
36 participants
INTERVENTIONAL
2020-09-21
2021-01-11
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1 Study of TT-00920 in Healthy Subjects
NCT05355129
The Pharmacokinetics (PK), Safety, Tolerability of SR419 in Healthy Volunteers
NCT05012761
A Clinical Study to See How the Study Drug MT-4129 is Taken up by the Body in Healthy Volunteers
NCT02953132
A Single-And Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of WD-890 Tablets in Healthy Chinese Subjects
NCT06506591
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Administration of HS-10356 in Healthy Volunteers
NCT04652297
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is a randomized, double-blind, placebo-controlled, dose-escalation design study, including three cohorts and 36 healthy participants. Within each cohort, participant will receive Qishenyiqi dripping pills at the selected dose level by oral administration three times a day for 28 consecutive days.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active dosage group 1
Qishenyiqi dripping pills, 3.12g, oral, three times a day
Qishenyiqi dripping pills, 6 bags
28 consecutive days
Active dosage group 2
Qishenyiqi dripping pills, 4.68g, oral, three times a day
Qishenyiqi dripping pills, 9 bags
28 consecutive days
Active dosage group 3
Qishenyiqi dripping pills, 6.24g, oral, three times a day
Qishenyiqi dripping pills, 12 bags
28 consecutive days
Control dosage group 1
Qishenyiqi dripping pills placebo, 3.12g, oral, three times a day
Qishenyiqi dripping pills placebo, 6 bags
28 consecutive days
Control dosage group 2
Qishenyiqi dripping pills placebo, 4.68g, oral, three times a day
Qishenyiqi dripping pills placebo, 9 bags
28 consecutive days
Control dosage group 3
Qishenyiqi dripping pills placebo, 6.24g, oral, three times a day
Qishenyiqi dripping pills placebo, 12 bags
28 consecutive days
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Qishenyiqi dripping pills, 6 bags
28 consecutive days
Qishenyiqi dripping pills, 9 bags
28 consecutive days
Qishenyiqi dripping pills, 12 bags
28 consecutive days
Qishenyiqi dripping pills placebo, 6 bags
28 consecutive days
Qishenyiqi dripping pills placebo, 9 bags
28 consecutive days
Qishenyiqi dripping pills placebo, 12 bags
28 consecutive days
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participants weigh at least 50.0 kg in male and 45.0 kg in female with a body mass index of all subjects between 19 and 26kg/m2 (including the boundary value);
* Participants are willing to have no pregnancy program and take effective contraceptive measures voluntarily since signing informed consent form to 3 months after the last administration;
* Participants are willing to sign Independent Ethics Committee (IEC)-approved informed consent form and able to understand and comply with study procedures.
Exclusion Criteria
* Participants with diseases or physiological conditions that may affect the study, including but not limited to diseases of the nervous, mental, respiratory, cardiovascular, digestive, blood and lymphatic, endocrine, musculoskeletal systems, liver and kidney dysfunction;
* Participants who have any clinically significant abnormalities in vital signs, physical examination, electrocardiogram, chest radiograph, abdominal ultrasound and laboratory examination;
* Participants who have positive test for hepatitis B virus surface antigen (except surface antibodies), hepatitis C virus antibody, human immunodeficiency virus antibody and treponema pallidum antibody;
* Women who are in the state of pregnancy or lactation;
* Participants who have a history of drug abuse or a positive test result for drug abuse at screening;
* Participants who have smoked more than 5 cigarette per day or used a considerable amount of nicotine-containing products within the previous 3 months, and could not quit smoking during the experiment;
* Participants who have been drinking more than 14 units of alcohol per week within the previous 3 months (1 unit ≈285 mL beer with 3.5% alcohol or 25 mL spirits with 40% alcohol or 85 mL wines with 12% alcohol), or positive test for alcohol, or could not abstain from drinking during the trial;
* Participants who have taken any prescription drugs (including prescription, nonprescription, herbal medicine, dietary supplement such as vitamin product and calcium tablet) within 4 weeks before administration of investigational drugs;
* Participants who have difficulty in venous blood collection or history of fainting blood or needles;
* Participants who have participated in any drug clinical trial within 3 months and have taken the experimental drug or plan to participate in other clinical trials during the trial period;
* Participants who have donated or lost blood ≥200 mL within 3 months or received blood transfusion or used blood products, or have blood donation plan during the trial period;
* Judged by the investigator, participants have poor compliance or have other factors such as clinical, social or family that should not be included in the trial.
18 Years
50 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tasly Pharmaceutical Group Co., Ltd
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The First Teaching Hospital of Tianjin University of TCM
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TSL-TCM-QSYQDW-I
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.